CN106581010B - 一种气溶胶制剂及定量吸入气雾剂 - Google Patents
一种气溶胶制剂及定量吸入气雾剂 Download PDFInfo
- Publication number
- CN106581010B CN106581010B CN201611235496.6A CN201611235496A CN106581010B CN 106581010 B CN106581010 B CN 106581010B CN 201611235496 A CN201611235496 A CN 201611235496A CN 106581010 B CN106581010 B CN 106581010B
- Authority
- CN
- China
- Prior art keywords
- aerosol
- preparation
- aerosol preparation
- content
- pvpk25
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 118
- 238000002360 preparation method Methods 0.000 title claims abstract description 88
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims abstract description 28
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 22
- 229960004436 budesonide Drugs 0.000 claims abstract description 22
- 239000003380 propellant Substances 0.000 claims abstract description 20
- 239000000470 constituent Substances 0.000 claims abstract description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 14
- 239000001530 fumaric acid Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 4
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 29
- 229940079593 drug Drugs 0.000 abstract description 26
- 239000008187 granular material Substances 0.000 abstract description 10
- 230000002776 aggregation Effects 0.000 abstract description 8
- 238000004220 aggregation Methods 0.000 abstract description 8
- 239000007921 spray Substances 0.000 abstract description 8
- 239000010419 fine particle Substances 0.000 abstract description 4
- 239000002245 particle Substances 0.000 description 40
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 15
- 229960000193 formoterol fumarate Drugs 0.000 description 15
- 239000000314 lubricant Substances 0.000 description 15
- 239000000375 suspending agent Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000004980 dosimetry Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 6
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical compound [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611235496.6A CN106581010B (zh) | 2016-12-28 | 2016-12-28 | 一种气溶胶制剂及定量吸入气雾剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611235496.6A CN106581010B (zh) | 2016-12-28 | 2016-12-28 | 一种气溶胶制剂及定量吸入气雾剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106581010A CN106581010A (zh) | 2017-04-26 |
CN106581010B true CN106581010B (zh) | 2019-03-05 |
Family
ID=58603042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611235496.6A Active CN106581010B (zh) | 2016-12-28 | 2016-12-28 | 一种气溶胶制剂及定量吸入气雾剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106581010B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464429B (zh) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | 一种吸入压力定量气雾剂药物组合物及其制备方法 |
CN109646400A (zh) * | 2018-12-25 | 2019-04-19 | 上海信谊百路达药业有限公司 | 一种布地奈德吸入气雾剂及其制备方法 |
CN110840864B (zh) * | 2019-12-20 | 2022-02-22 | 广州健康元呼吸药物工程技术有限公司 | 一种β2受体激动剂吸入气雾剂及包含该吸入气雾剂的产品 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1622802A (zh) * | 2002-02-01 | 2005-06-01 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
CN1625392A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
CN101032464A (zh) * | 2007-04-01 | 2007-09-12 | 杨喜鸿 | 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用 |
CN104225739A (zh) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
-
2016
- 2016-12-28 CN CN201611235496.6A patent/CN106581010B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1622802A (zh) * | 2002-02-01 | 2005-06-01 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
CN1625392A (zh) * | 2002-02-01 | 2005-06-08 | 阿斯利康(瑞典)有限公司 | 用于吸入的组合物 |
CN101032464A (zh) * | 2007-04-01 | 2007-09-12 | 杨喜鸿 | 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用 |
CN104225739A (zh) * | 2014-09-30 | 2014-12-24 | 四川普锐特医药科技有限责任公司 | 一种医用定量吸入气雾剂 |
Also Published As
Publication number | Publication date |
---|---|
CN106581010A (zh) | 2017-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Weers et al. | The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers | |
Virchow et al. | Importance of inhaler devices in the management of airway disease | |
Usmani et al. | Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols | |
Saeed et al. | Effects of fill volume and humidification on aerosol delivery during single-limb noninvasive ventilation | |
US8367734B1 (en) | Stable epinephrine suspension formulation with high inhalation delivery efficiency | |
Ferguson et al. | Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases | |
Biddiscombe et al. | Is there room for further innovation in inhaled therapy for airways disease? | |
Hatley et al. | Variability in delivered dose from pressurized metered-dose inhaler formulations due to a delay between shake and fire | |
Rottier et al. | Asthma medication delivery: mists and myths | |
JPH10503753A (ja) | エアゾールを含む麻酔用処方 | |
Corcoran et al. | Systemic delivery of atropine sulfate by the microdose dry-powder inhaler | |
JP2005539046A (ja) | 特異的な抗コリン作用薬、β−2アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 | |
CN106581010B (zh) | 一种气溶胶制剂及定量吸入气雾剂 | |
Vogelmeier et al. | Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma | |
Malerba et al. | Single Inhaler LABA/LAMA for COPD | |
Direkwatanachai et al. | Comparison of salbutamol efficacy in children-via the metered-dose inhaler (MDI) with Volumatic? spacer and via the dry powder inhaler, Easyhaler?, with the nebulizer-in mild to moderate asthma exacerbation: a multicenter, randomized study | |
Wallin et al. | Pulmonary drug delivery to older people | |
KR101475262B1 (ko) | 천식 치료에 사용되는 흡입용 복합 조성물 | |
Lexmond et al. | Drug delivery devices for inhaled medicines | |
Singh et al. | Novel aerosol delivery devices | |
TWI399202B (zh) | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 | |
JP2006517178A (ja) | 高い薬剤比率を有する吸入組成物 | |
Boules et al. | Effect of pressures and type of ventilation on aerosol delivery to chronic obstructive pulmonary disease patients | |
Kanth et al. | Nebulized mannitol, particle distribution, and cough in idiopathic pulmonary fibrosis | |
Anderson et al. | Aerosolized drug delivery in awake and anesthetized children to treat bronchospasm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Patentee after: Sichuan Pu et Pharmaceutical Co.,Ltd. Address before: No. 15 high tech Zone Gaopeng road in Chengdu city of Sichuan Province in 610000 Patentee before: SICHUAN PURUITE MEDICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 566 Antaiwu Road, Gaoxin District, Chengdu, Sichuan Province, 611730 Patentee after: Sichuan Pu et Pharmaceutical Co.,Ltd. Address before: No.15 Gaopeng Avenue, high tech Zone, Chengdu, Sichuan 610000 Patentee before: Sichuan Pu et Pharmaceutical Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |